A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 01 Mar 2017 This trial has been completed in Germany (End date:2016-10-18) as per European Clinical Trials Database record.
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Nov 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History